A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in Canada MONTREAL and SEATTLE, July 12, 2026 /PRNewswire/ -- Among the deadliest of brain...
HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in Canada MONTREAL and SEATTLE, July 12, 2026 /PRNewswire/ -- Among the deadliest of brain...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.